Researchers are on the verge of testing a fundamental hypothesis about how Alzheimer's disease evolves.
Amyloid-β, the peptide responsible for the ugly plaques coating the brains of victims of the disease, has long been considered the main culprit in triggering neuron death and subsequent mental decline. After years of complex drug discovery efforts, industry is putting that hypothesis to the test with a series of late-stage clinical trials for small molecules and antibodies that block amyloid-β.
Read More: The Amyloid Question: Alzheimer's researchers will soon know whether blocking amyloid-β can slow down the debilitating disease.
